The Global Insulin Delivery systems market is anticipated to grow at a CAGR of 9.10% between 2018 and 2026. The global insulin delivery systems market is in its growth stage. Rising incidences of type-1 diabetes cases, improving policies for reimbursement, and availability and affordability of devices will drive the market. The sales of insulin delivery systems are likely to increase with the development of devices. The insulin delivery systems market is primarily driven by the following factors:

• The upsurge in type-1 diabetes
• Availability of medication and delivery systems at the attached pharmacy stores
• Emphasis on self-management of diabetes

To know more about this report, request a free sample copy.

The important driver increasing growth in the global insulin delivery systems market is the growing prevalence of type-1 diabetes. Type 1 diabetes is an immune system disorder when the body assaults its own particular insulin creating pancreatic cells. In many patients, insulin is managed remotely for the duration of their lives to keep glucose from achieving a level that harms tissues and debilitate life. In spite of the fact that it represents just 5%-10% of all diabetes cases, it normally influences several years of a patients’ life than type 2 diabetes.

The Products of insulin delivery systems market are used extensively for various purposes.  Insulin syringes are categorized by three factors: needle length, needle gauge, and syringe capacity. Manufacturers offer syringes in an eclectic array of styles and sizes. Most syringes accessible today are disposable and come with micro-fine needles. Insulin pump therapy is being preferred as an alternative delivery method of administrating insulin over insulin pens and needles. Most insulin pens available in the market fall into one of these two groups: reusable insulin pens and disposable insulin pens. Insulin jet injectors are pen-like insulin conveyance devices that do not have a needle. These devices deliver small jets of insulin below great pressure just at the thrust of a button.

Stringent government regulations and the dearth of information are the major factors hindering the insulin delivery systems market. Insulin delivery systems is a highly regulated market. It faces stringent regulations and approval issues from government authorities, especially the US FDA. Many diabetologists are reluctant to use insulin devices in their practices as taking care of patients using this expertise is relatively arduous. Patients have abundant queries about the systems, and the data download, troubleshooting, and interpretation sometimes becomes cumbersome.

The Global Insulin Delivery systems market segments include products and end users.

Products are segmented into:

• Insulin syringes
• Insulin pumps
• Insulin pens
• Insulin jet injectors

End users are segmented into:

• Home care
• Hospitals and clinics
• Other end users

This report covers the present market conditions and the growth prospects of the global insulin delivery systems market for 2018-2026 and considered the revenue generated through the sales of insulin delivery systems for products as well as the end users to calculate the market size by considering 2017 as the base year.

Geographically, the global insulin delivery systems market has been segmented on the basis of four major regions, which include:

• North America – The United States & Canada
• Asia-Pacific – China, India, Australia, Japan, South Korea & Rest of APAC
• Europe – The United Kingdom, France, Germany, Italy, Spain, Russia & Rest of Europe
• Rest of World – Latin America & Rest of World

The Insulin Delivery systems market in North America is expected to hold the largest share by 2026 on account of the increased prevalence of diabetes and a rise in the number of overweight and obese people. Healthcare professionals are able to provide more care in diabetes management by supporting the use of new devices. The support from government has increased in recent years, ensuring deep penetration of insulin delivery devices. However, as per the current scenario, the market will see slow growth due to changes in reimbursement policies by Medicare in the US and Canada. On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region for the insulin delivery system market. Growing market potential in China, India, and other Asian countries has created additional opportunities to sell insulin delivery systems. Increased awareness about insulin delivery systems among the general diabetic population is expected to drive the market.

The global insulin delivery systems market is segmented on the basis of end users, who are further sub-divided into home care, hospitals and clinics and other end users. Hospitals are key end-users that greatly influence the market growth. They procure insulin delivery systems and other devices and engage closely with many suppliers, reimbursement authorities, and government organizations. The endocrinologists and physicians analyze the case and suggest better insulin delivery devices to patients, considering the type of device needed and the affordability of those devices by patients. The other end users in the Insulin delivery market include retail channels and marketers.

The major market players in the global insulin delivery systems market are:

• Becton, Dickinson, And Company
• Insulet Corporation
• Novo Nordisk A/S
• Sanofi
• Tandem Diabetes Care, Inc.

Company Profiles covers analysis of important players.

Becton, Dickinson, and Company (BD or ‘the company’) is a provider of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company operates in the US, Canada, Latin America, Europe, the Middle East, Africa and the Asia Pacific. Its pharmaceuticals segment focuses on research and development, along with production and marketing activities for all of Sanofi’s pharmaceuticals operations. The segment includes commercial operations of the following franchises: diabetes and cardiovascular, speciality care (multiple sclerosis, rare diseases, and oncology), established prescription products, consumer healthcare, and generics. Sanofi’s Pharmaceuticals segment portfolio includes a range of prescription medicines, generic medicines, and consumer health products.

Key findings of the global insulin delivery systems market:

• The rise in incidences of diabetes
• The rise in awareness about glucose monitoring devices
• Insulin pens are the largest contributor of insulin delivery market